Juul Agrees to Pay $438.5 Million in Settlement with 33 States

Sep.07.2022
Juul Agrees to Pay $438.5 Million in Settlement with 33 States
Juul settles with 33 states for $438.5 million and agrees to stop marketing to youth. Funds will go towards anti-vaping efforts.

E-cigarette company Juul has reached a settlement with 33 states, including Connecticut and Puerto Rico, agreeing to halt certain commercial practices, such as marketing to minors, and pay $438.5 million. The states have stated that the compensation will be used to implement bans on e-cigarettes and reduce nicotine activity.


Connecticut Attorney General William Tong stated in a press release that Juul's advertising campaigns have created a new generation of nicotine addicts.


They ruthlessly sell e-cigarette products to minors, manipulate their chemical composition to cater to non-smokers, use inappropriate age verification procedures, and mislead consumers about the nicotine content and addictive potential of their products. The consequences of this improper behavior on public health are still unclear.


The settlement marks the end of a two-year multi-state investigation. Juul has also agreed to refrain from any sponsorship or naming agreements, cease marketing to all youths, and avoid depicting individuals under the age of 35 in their advertisements.


After an appeal in court in June and reaching a temporary agreement with the U.S. Food and Drug Administration (FDA), Juul has continued to sell its products in the U.S. However, due to FDA regulation and legal battles, the company's market share in the vaping industry has significantly dropped. Back in May 2019, Juul held a dominant 75% market share, but according to VaporVoice, as of June 22, it had dropped to around 34.4%, with competitor Vuse narrowly surpassing Juul in the U.S. Meanwhile, the FDA is pushing for Juul to remove all of its products from U.S. shelves, continuing a thorough safety review of the products.


A spate of illnesses associated with the underground electronic cigarette market across the United States has further damaged Juul's public relations efforts.


In 2019, Juul Labs abandoned a campaign worth $11.6 million aimed at reversing San Francisco's ban on e-cigarette sales. In June 2020, the company announced that it was relocating its headquarters from San Francisco to Washington D.C. and expressed a desire to distance itself from the Silicon Valley startup culture and be closer to politicians and regulators.


According to a report by the Associated Press, Juul is still facing nine independent lawsuits from other states. These include a lawsuit filed by California and Los Angeles in November 2019, which focuses on the company's youth-targeted advertising and alleged failure to warn young consumers about the health risks of vaping. In June, a federal judge in San Francisco allowed a lawsuit against Juul Labs and parent company Altria Group Inc. to proceed on various issues related to misleading marketing.


The Associated Press reports that the company is still facing hundreds of individual consumer lawsuits.


A spokesperson for Juul stated in a press release to the Associated Press, "As we continue to fulfill our mission, we remain focused on our future of transitioning adult smokers from the leading cause of preventable death, combustible cigarettes, while combating underage use.


Statement


This article is sourced from compiled third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of its content. The translation of this article is solely intended for communication and research within the industry.


Due to limitations in our translation abilities, the translated article may not accurately reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any statements or positions related to domestic, Hong Kong, Macao, Taiwan, and foreign affairs.


The compiled information belongs to the original media and authors in terms of copyright. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
According to Swiss media outlet Blick, local authorities are strengthening compliance checks on vape products, nicotine pouches and other tobacco-related products following the implementation of Switzerland’s revised Tobacco Products Act. A Basel laboratory tested 32 disposable vapes and e-liquids, with only three meeting regulatory requirements and 21 products banned from sale. Swiss authorities are also expanding retail inspections, laboratory testing and youth purchase checks to enforce the new tobacco and nicotine product rules.
Aug.12
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26